Vor Adds RemeGen RC298 to Autoimmune License

Company Vor Bio; RemeGen Event Type License amendment Modality Engineered TACI-Fc fusion protein (long-acting) Asset RC298 Target BAFF; APRIL Disease Area Autoimmune disease Summary Vor Bio and China-based RemeGen amended their existing telitacicept license on November 12 to add RC298, a preclinical long-acting BAFF/APRIL inhibitor,…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *